Search Results

Cordis Names Dr. George Adams as Chief Medical Officer

December 10, 2021—Cordis announced that it has named George Adams, MD, as Chief Medical Officer.

CSI Releases 30-Day Results From Liberty 360° Study

August 11, 2016—Cardiovascular Systems, Inc. (CSI) announced that procedural and 30-day results from its LIBERTY 360° study were released in a late-breaking presentation at the 2016 Amputation Prevention Symposium (AMP) in Chicago, Illinois.

Data Presented From Mercator MedSystems' DANCE Trial

February 8, 2017—Mercator MedSystems, Inc. announced that the National Coprincipal Investigators of the company's DANCE trial recently presented comprehensive 13-month data.

SoundBite Marks First Use of Active Wire 0.014-Inch Platform to Treat CTOs in CLI

June 2, 2021—SoundBite Medical Solutions Inc. (SBMS) announced the first use of its active wire 0.014-inch platform in the United States for the treatment of critical limb ischemia (CLI) in patients with heavily calcified lower limb chronic total occlusions (CTO).

Six-Month Data From Intact Vascular TOBA II BTK Trial Presented

November 6, 2019—Intact Vascular, Inc. announced that the 6-month results of its Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial achieved all primary (P < .0001) and secondary endpoints with very low rates of major amputation and all-cause death.

Intact Vascular's TOBA II BTK Pivotal IDE Study Approved by FDA

October 31, 2016—Intact Vascular, Inc. announced that the US Food and Drug Administration (FDA) granted staged approval for the company’s investigational device exemption application to begin the Tack Optimized Balloon Angioplasty II BTK (TOBA II BTK) clinical study, which will examine the safety and efficacy of Intact’s Tack endovascular system when used to repair dissections in below-the-knee (BTK) arteries after percutaneous transluminal angioplasty treatment for critical limb ischemia (CLI).

Philips’ Tack Endovascular System Shows Sustained Efficacy in 2-Year TOBA II BTK Data

June 3, 2021—Royal Philips announced results from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial of the company’s Tack endovascular system (4F), a dissection repair device.

FDA Approves Intact Vascular's Tack Endovascular System for BTK Dissection Repair

April 14, 2020—Intact Vascular, Inc. announced FDA approval of its Tack (4-F) endovascular system for repair of postangioplasty dissections in the mid/distal popliteal, tibial, and/or peroneal below-the-knee (BTK) arteries ranging in diameter from 1.5 to 4.5 mm.

MedAlliance Selution SLR Receives FDA IDE Approval for SFA Study

August 9, 2022—MedAlliance announced that the company’s Selution SLR sirolimus-eluting balloon has received conditional FDA investigational device exemption (IDE) approval to initiate a pivotal clinical trial of the device for the treatment of occlusive disease of the superficial femoral artery (SFA).

Philips Tack Endovascular System Safety and Efficacy Evaluated in TOBA II BTK at 3-Year Analysis

June 13, 2022—Royal Philips announced the latest results from the TOBA II below-the-knee (BTK) clinical trial of the company’s Tack (4F) endovascular system.

Transit Scientific’s XO Cross Catheter Platform Used to Treat Complex CLI With Pedal Artery Retrograde Access

August 1, 2022—Transit Scientific reported that multiple peripheral vascular procedures were performed with the company’s XO Cross catheter platform using pedal retrograde access to treat complex critical limb ischemia (CLI).

Shockwave Launches S4 Lithotripsy Catheter for BTK Arteries

November 4, 2019—Shockwave Medical, Inc. announced the commercial availability of the Shockwave S4 peripheral intravascular lithotripsy (IVL) catheter in select regions.

Intact Vascular Completes Enrollment for TOBA II BTK Trial

January 3, 2019—Intact Vascular, Inc. announced that it has completed enrollment ahead of schedule for its TOBA II BTK clinical trial.